Image source: Adobe
Neurotechnologies, that is, technologies for measuring, analyzing, or influencing neural activity, are no longer just a promise of future research. One specific subfield of this is brain-computer interfaces (BCIs), which are direct communication channels between the brain and an external device. Both are evolving into a regulated medical technology sector with the first clinically validated applications. For example, the U.S. Food and Drug Administration (FDA, the U.S. regulatory agency for medical devices and drugs) published its own guidance on implantable BCIs for patients with paralysis or amputations as early as 2021. In the EU, the Medical Device Regulation (EU-MDR) provides the binding framework. Depending on how the market is defined, market research firms currently estimate the global neurotechnology market at around 15 to 20 billion U.S. dollars. It is driven primarily by neurostimulation (the targeted electrical stimulation of nerve tissue). A broader definition of the neuroscience market, which also includes imaging and research equipment, totals around 50 billion U.S. dollars. The crucial question is no longer whether the technology works, but rather which companies have the necessary expertise to bring together clinical evidence, regulatory approval, and patient care.
Regulatory maturity is a mark of quality, not an obstacle. In the U.S., the FDA classifies implantable BCIs under existing medical device pathways. Companies must demonstrate biocompatibility, cybersecurity, software validation, and long-term stability. In the EU, by contrast, implantable neurotechnologies intended for medical use are typically classified as Class III products, i.e., products in the highest risk class for medical devices. This requires a clinical evaluation, a certified quality management system, and the involvement of a Notified Body. A Notified Body is an independent testing organization that evaluates higher-risk-class products in accordance with the EU MDR.
Products without a medical intended use are also important: Devices that stimulate the brain through the skull using electrical currents or magnetic fields have also been classified as Class III since the Implementing Regulation (EU) 2022/2347, even if they are marketed to enhance concentration. For professionals in the field of “Regulatory Affairs” (specializing in approval strategies and communication with regulatory authorities), this creates structured career paths that are becoming increasingly important.
There is an important distinction between therapeutic applications and lifestyle products, which include, for example, wellness gadgets and concentration apps. The two follow fundamentally different regulatory and clinical rationales. In the therapeutic field, the following applications are particularly relevant:
The company Medtronic illustrates just how quickly these categories are converging: In early 2025, it received CE marking and FDA approval for an adaptive deep brain stimulation system for Parkinson’s disease. With this system, the stimulation is adjusted in real time based on the patient’s brain signals. Implantable BCIs in the narrower sense, such as those from Synchron and Neuralink, on the other hand, are still in clinical trials. They have not yet received market approval.
Clinical evidence is the key differentiator for approval, reimbursement, and acceptance. In our industries, we observe that candidates find this very connection between technical work and measurable patient benefit particularly motivating.
The structural shortage of skilled workers in neurotechnology is not caused by a lack of neuroscientists, but rather by a lack of candidates with interdisciplinary backgrounds. We are primarily looking for individuals with the following profiles:
Competition for these profiles comes from established companies in the medical technology, pharmaceutical, AI, and semiconductor sectors. The clinical and regulatory learning curves are long. Career transitions are therefore a realistic option and often the fastest route: Professionals from the medical technology sector bring experience in implant and risk management. Individuals with a background in the pharmaceutical industry are familiar with GCP (Good Clinical Practice, an international standard for the planning and documentation of clinical trials) and regulatory strategy. IT professionals can enter the field through signal processing and embedded systems, but they also need an understanding of clinical validation and patient safety. Companies that expand their talent sourcing to include related skill sets are significantly more successful in recruiting.
The market is currently in a phase where the technical foundations are in place, but many products and standards are still in the development stage. Early specialization creates visibility and niche expertise. Potential career paths range from individual contributor (subject matter expert without personnel responsibility) in the fields of neuroengineering, regulatory affairs, or signal processing to program management and medical affairs (the medical-scientific interface between companies, physicians, and the professional community).
Startups offer broad responsibilities and steep learning curves, but also greater uncertainty. Established medtech companies offer structured processes and resources, but with more narrowly defined areas of responsibility. In our consulting practice, we regularly observe that candidates with a clear “bridge” profile, meaning a strong core competency combined with an additional regulatory or clinical dimension, have significantly better negotiating positions. For companies, the rule is: A compelling employer positioning should specify concrete details such as the development phase, clinical partners, product roadmap, and areas of responsibility rather than abstract promises.
The growth market for neurotechnology and brain-computer interfaces is underpinned by regulatory frameworks and the first clinically validated products, and is not based on speculation. The key factors remain the combination of safety, clinical evidence, regulatory compliance, suitability for everyday use, and eligibility for reimbursement.
If you are looking for qualified and motivated specialists and executives for your company, we can support you with our specialized network. Particularly in neurotechnology and related fields of medical technology and life sciences, we identify interdisciplinary candidates who combine technical, clinical, and regulatory expertise. For over 15 years, the recruitment consultants at BESTMINDS have been filling vacancies in the medical technology, healthcare, life sciences / pharma, IT / media, and energy / utility sectors with a wealth of expertise and dedication. We find the right candidates for you in a fair, loyal, and discreet manner. Contact us for a no-obligation initial consultation so that we can fill your vacancies quickly and effectively.
